Senolytic Therapies for Aging

Senescent cells accumulate with age and secrete inflammatory compounds driving cardiovascular disease and Alzheimer disease. Senolytics eliminate these zombie cells. Dasatinib plus quercetin combination extended mouse healthy lifespan by 36 percent. Mayo Clinic first human trial showed physical function improvements. Unity Biotechnology is in Phase 2 for knee osteoarthritis. By 2030 senolytics may represent the first class of drugs explicitly treating aging as a disease.